CaptBeer, This is why JT sucks! He never took effective measures to circumvent this problem...Even now I would bet that many generic Vascepa scrips are eventually being filled as generic Lovaza. Why? Because the cost of generic Lovaza is substantially lower than the cost of either generic or branded Vascepa. So even if the Du-saster is reversed it still will not make the Lovaza problem go away. The sooner AMRN is placed into the hands of BP the quicker that competent executives can effectively handle these problems.
Elegant analysis Capt Beer I agree with others here that the enemy is more inappropriate Lovaza prescription/substitution than it is generic Vascepa at this time. HK